{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:24:43Z","timestamp":1790785483330,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":2141,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100013216","name":"Imperial","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013216","id-type":"DOI","asserted-by":"crossref"}]},{"name":"College's Experimental Cancer Medicine Center (ECMC), Cancer Research UK (CRUK) Clinical Center and Biomedical Research Centre"},{"name":"NIHR Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and Institute of Cancer Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1093\/annonc\/mdt515","type":"journal-article","created":{"date-parts":[[2013,12,7]],"date-time":"2013-12-07T01:15:16Z","timestamp":1386378916000},"page":"160-165","source":"Crossref","is-referenced-by-count":32,"title":["Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study"],"prefix":"10.1016","volume":"25","author":[{"given":"C.","family":"Fotopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mainwaring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bidzinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.B.","family":"Vermorken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"Ghamande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Harnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"Del Prete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Spaczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Blagden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Gabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9522","key":"10.1093\/annonc\/mdt515_bb0010","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(06)68671-6","article-title":"Surgery for ovarian cancer: how to improve survival","volume":"367","author":"Bristow","year":"2006","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdt515_bb0015","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1040-8428(99)00049-9","article-title":"Role of chemotherapy in relapsed ovarian cancer","volume":"32","author":"Colombo","year":"1999","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdt515_bb0020","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdt515_bb0025","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/annonc\/mdp198","article-title":"Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules to patients with relapsed, platinum-sensitive, advanced ovarian cancer","volume":"20","author":"Del Campo","year":"2009","journal-title":"Ann Oncol"},{"issue":"42","key":"10.1093\/annonc\/mdt515_bb0030","first-page":"140","article-title":"Dose density and altered scheduling of adjuvant chemotherapy in ovarian cancer: teaching old dogs new tricks?","volume":"8","author":"Gabra","year":"2009","journal-title":"Discov Med"},{"key":"10.1093\/annonc\/mdt515_bb0035","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/sj.bjc.6600002","article-title":"Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer","volume":"86","author":"van der Burg","year":"2002","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1093\/annonc\/mdt515_bb0040","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1023\/A:1013558501425","article-title":"Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer","volume":"12","author":"Meyer","year":"2001","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdt515_bb0045","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.bjc.6604914","article-title":"Extended weekly dose-dense paclitaxel\/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer","volume":"100","author":"Sharma","year":"2009","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdt515_bb0050","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ygyno.2012.10.004","article-title":"The \u2018Leuven\u2019 paclitaxel\/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study","volume":"128","author":"Cadron","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdt515_bb0055","first-page":"386","article-title":"Weekly single-agent carboplatin in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma","volume":"26","author":"Piura","year":"2005","journal-title":"Eur J Gynaecol Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdt515_bb0060","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.ejca.2012.11.027","article-title":"Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer","volume":"49","author":"van der Burg","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdt515_bb0065","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/cncr.21633","article-title":"Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells","volume":"106","author":"Alvero","year":"2006","journal-title":"Cancer"},{"issue":"10","key":"10.1093\/annonc\/mdt515_bb0070","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1002\/ijc.21682","article-title":"Phenoxodiol, an experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumour effects","volume":"118","author":"Gamble","year":"2006","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1093\/annonc\/mdt515_bb0075","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1517\/14656560902837980","article-title":"Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs","volume":"10","author":"Silasi","year":"2009","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"10.1093\/annonc\/mdt515_bb0080","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/IGC.0b013e3182126f05","article-title":"Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum\/taxane-refractory\/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers","volume":"21","author":"Kelly","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mdt515_bb0085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1093\/annonc\/mdt515_bb0090","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST-1.1 and CA-125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"10.1093\/annonc\/mdt515_bb0095","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2002.09.130","article-title":"Phase II trial of weekly single-agent paclitaxel in platinum\/paclitaxel-refractory ovarian cancer","volume":"20","author":"Markman","year":"2002","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdt515_bb0100","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/ijgc-00009577-200303000-00007","article-title":"Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer","volume":"13","author":"Ghamande","year":"2003","journal-title":"Int J Gynecol Cancer"},{"issue":"Suppl","key":"10.1093\/annonc\/mdt515_bb0105","article-title":"AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)","volume":"30","author":"Eric","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdt515_bb0110","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s12033-008-9132-x","article-title":"Phenoxodiol treatment alters the subsequent response of ENOX2 (tNOX) and growth of hela cells to paclitaxel and cisplatin","volume":"42","author":"Morr\u00e9","year":"2009","journal-title":"Mol Biotechnol"},{"key":"10.1093\/annonc\/mdt515_bb0115","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1479-5876-5-6","article-title":"The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization","volume":"5","author":"Kluger","year":"2007","journal-title":"J Transl Med"},{"issue":"Suppl","key":"10.1093\/annonc\/mdt515_bb0120","first-page":"15s","article-title":"Multicenter randomized phase III trial of 3-weekly paclitaxel\/platinum versus weekly paclitaxel\/platinum induction therapy followed by PC3w maintenance therapy in advanced epithelial ovarian cancer","volume":"27","author":"Burg","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt515_bb0125","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1200\/JCO.2004.03.017","article-title":"Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial","volume":"22","author":"Bolis","year":"2004","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdt515_bb0130","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.ejca.2012.01.006","article-title":"Evaluation of paclitaxel\/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer","volume":"48","author":"Torfs","year":"2012","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1093\/annonc\/mdt515_bb0135","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.critrevonc.2007.12.005","article-title":"A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study","volume":"66","author":"Pignata","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"issue":"Suppl 8","key":"10.1093\/annonc\/mdt515_bb0140","doi-asserted-by":"crossref","first-page":"viii33","DOI":"10.1093\/annonc\/mdr514","article-title":"Dose-dense therapy is of benefit in primary treatment of ovarian cancer: contra","volume":"22","author":"van der Burg","year":"2011","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdt515_bb0145","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ygyno.2009.08.021","article-title":"The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer","volume":"115","author":"Hoekstra","year":"2009","journal-title":"Gynecol Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419359678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419359678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/25\/1\/160\/16701643\/mdt515.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:29:14Z","timestamp":1624519754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419359678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0923753419359678"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt515","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}